fda semaglutide warning september 2025 Beyond the Headlines: Letters to GLP-1 Compounders FDA issued 25 warning letters

Hikma Pharmaceuticals (LON: $HIK) won tentative approval for its generic this June

Thyroid function in adults with praderwilli syndrome

The investigators didnt attempt to control for weight loss effects by imposing calorie restriction or other weight-matching strategies on the placebo group, nor did they perform any analyses on their data that might correct for the weight loss discrepancy

If weight loss or glycemic control is the goal today, tirzepatide is the option with an approval, a known supply chain, and an established safety database

Commitment to Quality Quality is at the core of everything we do

Many literature reports describe a variable rate of LD, under different settings, like adult outpatients treated by primary care physicians and others referring to diabetes centers or even children